Franklin Resources Inc. continued to hold its position in Proteostasis Therapeutics, Inc. (NASDAQ:PTI) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 243,400 shares of the company’s stock at the close of the second quarter. Franklin Resources Inc. owned about 0.97% of Proteostasis Therapeutics worth $1,139,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in PTI. Teachers Advisors LLC raised its stake in shares of Proteostasis Therapeutics by 21.4% during the fourth quarter. Teachers Advisors LLC now owns 12,617 shares of the company’s stock valued at $155,000 after acquiring an additional 2,223 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Proteostasis Therapeutics during the first quarter worth about $100,000. Bank of New York Mellon Corp grew its stake in shares of Proteostasis Therapeutics by 17.3% in the first quarter. Bank of New York Mellon Corp now owns 34,964 shares of the company’s stock worth $273,000 after purchasing an additional 5,153 shares during the last quarter. TD Asset Management Inc. bought a new stake in shares of Proteostasis Therapeutics in the first quarter worth about $199,000. Finally, Trexquant Investment LP grew its stake in shares of Proteostasis Therapeutics by 1.0% in the first quarter. Trexquant Investment LP now owns 19,790 shares of the company’s stock worth $155,000 after purchasing an additional 190 shares during the last quarter. Hedge funds and other institutional investors own 73.71% of the company’s stock.

Shares of Proteostasis Therapeutics, Inc. (PTI) opened at 2.10 on Monday. The company has a 50-day moving average price of $2.08 and a 200-day moving average price of $5.13. The stock’s market cap is $52.71 million. Proteostasis Therapeutics, Inc. has a 52 week low of $1.71 and a 52 week high of $16.67.

A number of research analysts recently issued reports on the company. Zacks Investment Research downgraded Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Proteostasis Therapeutics in a research report on Friday, June 30th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $9.00 price objective (down previously from $17.00) on shares of Proteostasis Therapeutics in a report on Wednesday, August 16th.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/proteostasis-therapeutics-inc-pti-holdings-maintained-by-franklin-resources-inc/1602348.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Want to see what other hedge funds are holding PTI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Proteostasis Therapeutics, Inc. (NASDAQ:PTI).

Institutional Ownership by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.